SAN DIEGO, May 6, 2010 (GLOBE NEWSWIRE) -- OccuLogix, Inc., dba TearLab Corporation ("TearLab") (Nasdaq:TEAR) (TSX:TLB) today announced today that a variety of paper and poster presentations given at the 2010 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) highlighted tear film osmolarity as the preferred tool in the evaluation of patients suffering from Dry Eye Disease ("DED") and further validated TearLab's™ unique ability to accurately measure subtle changes in the condition of the ocular surface.
